1,305,795 Shares in Indivior PLC $INDV Acquired by Newtyn Management LLC

Newtyn Management LLC acquired a new position in shares of Indivior PLC (NASDAQ:INDV) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,305,795 shares of the company’s stock, valued at approximately $53,577,000. Indivior accounts for 6.8% of Newtyn Management LLC’s investment portfolio, making the stock its 3rd biggest position. Newtyn Management LLC owned about 1.11% of Indivior as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP purchased a new stake in shares of Indivior in the 3rd quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares during the period. Rockefeller Capital Management L.P. increased its stake in shares of Indivior by 512.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after buying an additional 1,076 shares during the period. GAMMA Investing LLC bought a new stake in shares of Indivior in the second quarter valued at about $66,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Indivior in the second quarter valued at about $26,000. 60.33% of the stock is owned by institutional investors.

Insider Activity at Indivior

In other news, CAO Woodrow D. Anderson purchased 1,500 shares of the stock in a transaction on Thursday, August 27th. The stock was bought at an average price of $35.69 per share, with a total value of $53,535.00. Following the transaction, the chief accounting officer owned 27,638 shares in the company, valued at $986,400.22. The trade was a 5.74% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christian Heidbreder sold 18,586 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the completion of the transaction, the insider owned 209,337 shares of the company’s stock, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by insiders.

Indivior Price Performance

Shares of INDV opened at $34.87 on Monday. The company has a market cap of $4.12 billion, a price-to-earnings ratio of 12.50 and a beta of 0.86. Indivior PLC has a twelve month low of $22.22 and a twelve month high of $42.81. The company has a 50 day moving average of $39.33 and a two-hundred day moving average of $36.01.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%.The business had revenue of $343.00 million for the quarter. On average, sell-side analysts expect that Indivior PLC will post 3.66 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on INDV shares. Barclays dropped their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Craig Hallum reiterated a “buy” rating and set a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Finally, Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.17.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.